148 related articles for article (PubMed ID: 34783716)
21. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
[TBL] [Abstract][Full Text] [Related]
22. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
23. [Von Hippel-Lindau disease: recent genetic progress and patient management. Francophone Study Group of von Hippel-Lindau Disease (GEFVH)].
Richard S; Giraud S; Beroud C; Caron J; Penfornis F; Baudin E; Niccoli-Sire P; Murat A; Schlumberger M; Plouin PF; Conte-Devolx B
Ann Endocrinol (Paris); 1998; 59(6):452-8. PubMed ID: 10189987
[TBL] [Abstract][Full Text] [Related]
24. Von Hippel-Lindau disease and sporadic renal cell carcinoma.
Zbar B
Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521
[TBL] [Abstract][Full Text] [Related]
25. Radiological evaluation, management, and surveillance of renal masses in Von Hippel-Lindau disease.
Meister M; Choyke P; Anderson C; Patel U
Clin Radiol; 2009 Jun; 64(6):589-600. PubMed ID: 19414081
[TBL] [Abstract][Full Text] [Related]
26. Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions.
Gallou C; Chauveau D; Richard S; Joly D; Giraud S; Olschwang S; Martin N; Saquet C; Chrétien Y; Méjean A; Correas JM; Benoît G; Colombeau P; Grünfeld JP; Junien C; Béroud C
Hum Mutat; 2004 Sep; 24(3):215-24. PubMed ID: 15300849
[TBL] [Abstract][Full Text] [Related]
27. Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.
Sorrell AD; Lee S; Stolle C; Ellenhorn J; Grix A; Kaelin WG; Weitzel JN
Clin Genet; 2011 Jun; 79(6):539-45. PubMed ID: 20560986
[TBL] [Abstract][Full Text] [Related]
28. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
29. The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis.
Decker HJ; Weidt EJ; Brieger J
Cancer Genet Cytogenet; 1997 Jan; 93(1):74-83. PubMed ID: 9062583
[TBL] [Abstract][Full Text] [Related]
30. Genotype-phenotype correlations, and retinal function and structure in von Hippel-Lindau disease.
Wittström E; Nordling M; Andréasson S
Ophthalmic Genet; 2014 Jun; 35(2):91-106. PubMed ID: 24555745
[TBL] [Abstract][Full Text] [Related]
31. [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer].
Moch H
Pathologe; 2008 Nov; 29 Suppl 2():149-52. PubMed ID: 18751708
[TBL] [Abstract][Full Text] [Related]
32. von Hippel-Lindau disease: a clinical and scientific review.
Maher ER; Neumann HP; Richard S
Eur J Hum Genet; 2011 Jun; 19(6):617-23. PubMed ID: 21386872
[TBL] [Abstract][Full Text] [Related]
33. The HIF and other quandaries in VHL disease.
Tarade D; Ohh M
Oncogene; 2018 Jan; 37(2):139-147. PubMed ID: 28925400
[TBL] [Abstract][Full Text] [Related]
34. [Endolymphatic sac tumor with von Hippel-Lindau disease: report of two cases with testing of von Hippel-Lindau gene].
Su Y; Shen WD; Wang CC; Han WJ; Liu J; Hou ZH; Song ZG; Huang DL; Han DY; Yang SM
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 Nov; 48(11):913-8. PubMed ID: 24444636
[TBL] [Abstract][Full Text] [Related]
35. A Case of von Hippel-Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas.
Heo SJ; Lee CK; Hahn KY; Kim G; Hur H; Choi SH; Han KS; Cho A; Jung M
Cancer Res Treat; 2016 Jan; 48(1):409-14. PubMed ID: 25715769
[TBL] [Abstract][Full Text] [Related]
36. Third International Meeting on von Hippel-Lindau disease.
Zbar B; Kaelin W; Maher E; Richard S
Cancer Res; 1999 May; 59(9):2251-3. PubMed ID: 10232616
[TBL] [Abstract][Full Text] [Related]
37. Von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment.
Shuin T; Yamasaki I; Tamura K; Okuda H; Furihata M; Ashida S
Jpn J Clin Oncol; 2006 Jun; 36(6):337-43. PubMed ID: 16818478
[TBL] [Abstract][Full Text] [Related]
38. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene.
Chen F; Kishida T; Duh FM; Renbaum P; Orcutt ML; Schmidt L; Zbar B
Cancer Res; 1995 Nov; 55(21):4804-7. PubMed ID: 7585510
[TBL] [Abstract][Full Text] [Related]
39. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
Lubensky IA; Gnarra JR; Bertheau P; Walther MM; Linehan WM; Zhuang Z
Am J Pathol; 1996 Dec; 149(6):2089-94. PubMed ID: 8952541
[TBL] [Abstract][Full Text] [Related]
40. Identification of somatic mutations in the von Hippel-Lindau (VHL) gene in a patient with renal cell carcinoma.
Wang WC; Chen HJ; Tseng YH; Lai YC
J Formos Med Assoc; 2009 Nov; 108(11):886-93. PubMed ID: 19933033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
